A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: BIOLOGICAL: Immunotherapeutic SB719125 (Primary)
Sponsor: GlaxoSmithKline